Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.
Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Leoni P, Bacigalupo A. Olivieri A, et al. Among authors: bacigalupo a. Blood. 2013 Dec 12;122(25):4111-8. doi: 10.1182/blood-2013-05-494278. Epub 2013 Oct 23. Blood. 2013. PMID: 24152907 Free article. Clinical Trial.
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.
Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D. Guglielmi C, et al. Among authors: bacigalupo a. Blood. 2002 Jul 15;100(2):397-405. doi: 10.1182/blood.v100.2.397. Blood. 2002. PMID: 12091328 Free article.
Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation.
Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, Bregante S, Di Grazia C, Soracco M, Pitto A, Frassoni F, Bacigalupo A. Dominietto A, et al. Among authors: bacigalupo a. Blood. 2002 Dec 1;100(12):3930-4. doi: 10.1182/blood-2002-01-0339. Epub 2002 Aug 1. Blood. 2002. PMID: 12393584 Free article.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Corradini P, et al. Among authors: bacigalupo a. Blood. 2003 Sep 1;102(5):1927-9. doi: 10.1182/blood-2003-01-0189. Epub 2003 May 8. Blood. 2003. PMID: 12738666 Free article. Clinical Trial.
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R; Myeloproliferative Diseases-Research Consortium. Rondelli D, et al. Among authors: bacigalupo a. Blood. 2005 May 15;105(10):4115-9. doi: 10.1182/blood-2004-11-4299. Epub 2005 Jan 25. Blood. 2005. PMID: 15671439 Free article.
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF; Chronic Leukemia Working Party of the EBMT. Crawley C, et al. Among authors: bacigalupo a. Blood. 2005 Nov 1;106(9):2969-76. doi: 10.1182/blood-2004-09-3544. Epub 2005 Jul 5. Blood. 2005. PMID: 15998838 Free article.
Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.
Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dallorso S, Locasciulli A, Guidi S, Mordini N, Sica S, Cudillo L, Fagioli F, Selleri C, Bruno B, Arcese W, Bacigalupo A. Van Lint MT, et al. Among authors: bacigalupo a. Blood. 2006 May 15;107(10):4177-81. doi: 10.1182/blood-2005-12-4851. Epub 2006 Jan 31. Blood. 2006. PMID: 16449522 Free article. Clinical Trial.
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A; Gruppo Italiano Trapianti Midollo Osseo (GITMO). Bacigalupo A, et al. Biol Blood Marrow Transplant. 2006 May;12(5):560-5. doi: 10.1016/j.bbmt.2005.12.034. Biol Blood Marrow Transplant. 2006. PMID: 16635791 Free article. Clinical Trial.
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. Bruno B, et al. Among authors: bacigalupo a. Eur J Haematol. 2007 Apr;78(4):330-7. doi: 10.1111/j.1600-0609.2007.00816.x. Epub 2007 Feb 27. Eur J Haematol. 2007. PMID: 17331132 Clinical Trial.
838 results